Google's life sci­ences sis­ter plugs Big Phar­ma in­to the main­stream in a dig­i­tal over­haul of the clin­i­cal tri­al ...

7 years ago
Pharma

BioCryst shares are blast­ed as a PhI­II HAE 'suc­cess' un­der­whelms an­a­lysts

7 years ago
R&D
Pharma

Be­lea­guered Bio­gen faces the mu­sic as a ris­ing cho­rus of crit­ics push for a trans­for­ma­tive ap­proach to M&A

7 years ago
Deals
Pharma

Ger­many's Evotec ex­pands in­to bi­o­log­ics with up to $90M deal for Seat­tle's Just Bio­ther­a­peu­tics

7 years ago
Deals

PhI­II set­back mars Oc­u­lar's glau­co­ma drug/de­vice, though com­pa­ny re­mains 'en­cour­aged' by da­ta break­down

7 years ago
R&D

Mer­ck bets $2.2B on a small can­cer drug biotech, snatch­ing it out of the IPO line­up

7 years ago
Deals
R&D

Mer­ck­'s Keytru­da fails triple neg­a­tive breast can­cer piv­otal study

7 years ago
Pharma

Ad­di­tion­al back­ing arms Schrödinger with $110M in first ven­ture round — shin­ing a spot­light on its own pipeline

7 years ago
Financing

Take­da shares pos­i­tive Phase II­Ib da­ta; NIA grant for Phase II study on new oral Alzheimer's treat­ment

7 years ago
News Briefing

TRC Cap­i­tal's mi­ni-ten­der of­fer ir­ri­tates a flus­tered Bio­gen

7 years ago
Pharma

Can­cer re­search groups urge FDA to over­haul stan­dards for ear­ly cell ther­a­py tri­als, cut­ting time and cost. But will ...

7 years ago
R&D
Pharma

Some of the best con­nect­ed play­ers in the San Diego hub or­ga­nize launch round for an­oth­er biotech with an eye on ...

7 years ago
Startups
R&D

As UK biotech gains steam, Syn­cona launch­es new Treg play­er while Cam­bridge spin­out ex­pands Se­ries A

7 years ago
Financing
Startups

Long-term in­clisir­an da­ta sug­gest The Med­i­cines Com­pa­ny/Al­ny­lam drug will flour­ish in piv­otal study, dis­rupt 'bad' ...

7 years ago
R&D

$1.3B Keytru­da wind­fall will be used to ac­cel­er­ate trans­la­tion­al drug R&D in the UK

7 years ago
Startups
R&D

Dana-Far­ber’s 4-year le­gal bat­tle shines a light on the ori­gins of PD-1 re­search — forc­ing a reck­on­ing on who ...

7 years ago
People
R&D

Take­da re­ceives ad­di­tion­al FDA ap­proval for GI drug; Can­cer Re­search UK to test gem­c­itabine for ad­vanced pan­cre­at­ic ...

7 years ago
News Briefing

Un­der fire for Tru­va­da US pric­ing at House hear­ing, Gilead chief O'­Day touts R&D costs, as­serts gov­ern­ments patents ...

7 years ago
Pharma

EMA im­pos­es for­mal lim­it on Xel­janz pre­scrip­tion as reg­u­la­tors con­tin­ue to re­view safe­ty con­cerns

7 years ago
Pharma

Bio­gen ex­ec Paul McKen­zie heads to CSL as COO; Pul­ma­trix CEO re­signs

7 years ago
Peer Review

Ab­b­Vie con­cedes an­oth­er PhI­II can­cer drug flop as glioblas­toma de­feats lat­est as­sault

7 years ago
R&D

Fol­low­ing its lat­est set­back, Achillion posts some en­cour­ag­ing PoC da­ta for lead drug

7 years ago
R&D
Pharma

Take­da, Fra­zier cre­ate Phath­om Phar­ma­ceu­ti­cals to spur de­vel­op­ment of GI drug vono­prazan in $140M play

7 years ago
Pharma

Bet­ter than CAR-T? Al­ready prep­ping for a US launch, Mor­phoSys posts stel­lar DL­B­CL da­ta to field against No­var­tis, ...

7 years ago
R&D
First page Previous page 948949950951952953954 Next page Last page
A service from the Financial Times